The pharmaceutical giant Pfizer started clinical trials in the early stages of an experimental antiviral drug for the treatment of COVID-19.
The company announced The phase one trial of the drug, PF-07321332, is currently taking place in the USA on Tuesday.
Our country is in a historic battle against the Coronavirus. Add Changing America to you Facebook or Twitter feed to stay up to date with the news.
The treatment is a powerful protease inhibitor, the same technology used to treat HIV and hepatitis C. Protease inhibitors bind to a viral enzyme and prevent the virus from repeating in the cell.
Pfizer said preclinical studies have shown that the oral antiviral effect showed in vitro antiviral activity against SARS-CoV-2, as well as activity against other coronaviruses. This means that the treatment may be useful against future coronavirus threats.
To tackle the COVID-19 pandemic, vaccine prevention and effective treatment must be done for those who contract the virus. Given the way SARS-CoV-2 mutates and the continuing global impact of COVID-19, it seems likely that access to therapeutic options, as well as outside the pandemic, will be critical, ”said Mikeal Dolsten, scientist. head of Pfizer, said. , has in a statement.
Dolsten said the oral treatment can be prescribed to the patient at the first sign of infection, without the need for it in the hospital or in critical care.
Pfizer is also studying intravenous antiviral therapy for the treatment of COVID-19 used in a clinical trial with inpatients.
“Together, the two have the potential to create an end-to-end treatment paradigm that complements the vaccination,” Dolsten said.
In collaboration with the German company BioNTech, Pfizer was the first pharmaceutical company to receive emergency use approval from the Food and Drug Administration (FDA) for a COVID-19 vaccine.
Currently, the only FDA-approved antiviral treatment for COVID-19 is Gilead Remdesivir Therapy.
Pfizer says it will share pre-clinical data on its experimental pill on April 6.
READ MORE AS FROM THE CHANGE OF AMERICA
OBAMACARE SIGNS 200K NEW ENTERPRISES
NEW PSYCHEDELICS STUDY ALSO SUGGESTED PLACEBO WORKS
NEW STUDY WARNINGS PFIZER AND MODERNA COVID-19 BELKING SUBSTANCES MAY BE REDUCING EFFECTIVE TO SOUTH AFRICA VARIANT
1 IN 4 AMERICANS REFUSE TO GET COVID-19 VACCINE: POLL
YOU ARE SO FULLY AGAINST COVID-19. NOW WHAT?